Pro-Dex (NASDAQ:PDEX) First Quarter 2025 Results

Key Financial Results

• Revenue: US$14.9m (up 25% from 1Q 2024).
• Net income: US$2.47m (up from US$615.0k loss in 1Q 2024).
• Profit margin: 17% (up from net loss in 1Q 2024). The move to profitability was primarily driven by higher revenue.
• EPS: US$0.76 (up from US$0.17 loss in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pro-Dex Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates by 159%.

Looking ahead, revenue is expected to decline by 1.2% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in the US are expected to grow by 8.3%.

Performance of the American Medical Equipment industry.

The company's shares are up 27% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Pro-Dex that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.